Histogen Inc logo

HSTO - Histogen Inc News Story

$0.793 -0.0  -2.1%

Last Trade - 24/09/21

Micro Cap
Market Cap £24.2m
Enterprise Value £6.56m
Revenue £1.03m
Position in Universe 6262nd / 7172

Histogen and Amerimmune Report Publication on Emricasan in COVID-19

Wed 19th May, 2021 1:00pm
For best results when printing this announcement, please click on link below:

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a
clinical-stage therapeutics company focused on developing potential
first-in-class restorative therapeutics that ignite the body’s natural
process to repair and maintain healthy biological function and its partner,
Amerimmune, LLC, today reported the publication of the potential utility of
emricasan in COVID-19 in Allergy, the official Journal of the European Academy
of Allergy and Clinical Immunology.

Amerimmune, in collaboration with Dr. Raavi Gupta from SUNY Downstate Medical
Center and Dr. Lishomva Ndhlovu from Weill Cornell Medicine, demonstrated the
impact of caspases in multiple blood cells beyond the acute stage of the
disease. Their research concluded that caspases are elevated in patients with
co-morbidities and persisted into much later stages of the disease, also
referred to as long COVID. Moreover, the results were not just limited to the
elevation of caspase-1 in white blood cells. There was also an elevation of
caspase-3 in red blood cells (erythrocytes). These findings have potential
implications to understand the pathogenesis of complications of SARS-CoV2
infection such as extensive blood clot formation, resulting in significant
morbidity and mortality. The collaborative work of SUNY Downstate and Weill
Cornell Medical Center with Amerimmune demonstrated how in certain individuals
regarded as “high risk”, such as asthma, immune deficiencies and chronic
sinopulmonary disease, there is already increased baseline caspase-1
expression, potentially setting the stage for complications if they were to be
infected with SARS CoV2. All the assays used in this study were developed and
validated by Amerimmune. This study now leads to more research opportunities
to explore why some individuals develop worse outcomes, whereas some others
remain asymptomatic. Most importantly, the team showed that Emricasan, a
pan-caspase inhibitor, can effectively reduce the caspase expression in in
vitro, paving the way to the use of pan-caspase inhibition as a treatment
modality in COVID-19.

“Emricasan is a small molecule pan-caspase inhibitor that is administered
orally, which has been shown to reduce caspase related inflammation in
tissues. This therapeutic modality could address the events at the onset of
the COVID-19 process and may have the potential to prevent the down-stream
COVID-19 related complications,” said Oral Alpan, MD, CEO of Amerimmune.

“The findings from this important research support the potential of
emricasan as a treatment option for COVID-19 in the acute and long-haul phases
of the disease,” said Richard Pascoe, President and CEO of Histogen. “We
look forward to the anticipated completion of our ongoing Phase 1 Study in
mild- symptomatic COVID-19 patients at SUNY Downstate Medical Center, in the
second quarter of 2021.”  

The research paper entitled “Caspases in Moderate-Severe, Long COVID-19
Disease and the Therapeutic Potential of Caspase Inhibitors” has been
published in Allergy, the Journal of the European Academy of Allergy and
Clinical Immunology, and is currently available electronically at

About Emricasan

Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor
designed to reduce the activity of enzymes that mediate inflammation and
apoptosis. Histogen acquired certain rights to emricasan and other caspase
inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc.
in 2020. Histogen believes that by reducing the activity of these enzymes,
caspase inhibitors have the potential to interrupt the progression of a
variety of diseases. To date, emricasan has been studied in over 950 patients
in 19 completed clinical trials across a broad range of liver diseases. In
NASH cirrhosis patients in multiple clinical Phase II trials conducted by
Conatus, emricasan demonstrated rapid and sustained reductions in elevated
levels of key biomarkers of inflammation and cell death. Similarly, elevated
biomarkers are also believed to play a role in the severity and progression of

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing
potential first-in-class restorative therapeutics that ignite the body’s
natural process to repair and maintain healthy biological function.
Histogen’s innovative technology platform utilizes cell conditioned media
and extracellular matrix materials produced by hypoxia-induced multipotent
cells. Histogen’s proprietary, reproducible manufacturing process provides
targeted solutions across a broad range of therapeutic indications including
hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk
repair. For more information, please visit www.histogen.com.

About Amerimmune

Amerimmune LLC is a research center and immunology laboratory with a strong
focus on identifying underlying mechanisms of immune disorders. Amerimmune’s
mission is to bring relevant science, data, and diagnostic and therapeutic
solutions to diseases that involve the immune system. Amerimmune LLC is a
spinoff of Amerimmune Diagnostics LLC, which is focused on establishing a
network of physician-owned immunology labs across the United States.
Amerimmune Diagnostics’ clinical approach led to the development of the
innovative therapeutics’ technology upon which Amerimmune was founded. When
the COVID-19 pandemic emerged early this year, Amerimmune brought its
expertise to bear against this devastating disease. Amerimmune is a privately
held development-stage company based in Fairfax, VA. For more information and
to explore partnering opportunities, please visit www.amerimmune.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995 and other Federal securities laws. For example, we are using
forward-looking statements when we discuss Histogen’s future operations and
its ability to successfully initiate and complete clinical trials, obtain
clinical trial data and achieve regulatory milestones and related timing,
including those related to the completion of the Phase 1 study of emricasan
for the treatment of COVID-19 and receipt of top-line data; the nature,
strategy and focus of Histogen’s business; the sufficiency of Histogen’s
cash resources and Histogen’s ability to achieve value for its stockholders;
the sufficiency of Amerimmune’s cash resources and its ability to complete
the Phase 1 study of emricasan and achieve value for Histogen’s
stockholders; and the development and commercial potential and potential
benefits of any of Histogen’s product candidates, such as HST-001, and
HST-003, and the Collaborative Development and Commercialization Agreement
with Amerimmune and any other collaboration agreements. Histogen may not
actually achieve the plans, carry out the intentions or meet the expectations
or projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Because such
statements deal with future events and are based on Histogen’s current
expectations, they are subject to various risks and uncertainties and actual
results, performance or achievements of Histogen that could differ materially
from those described in or implied by the statements in this press release,
including: the uncertainties associated with the clinical development and
regulatory approval of Histogen’s product candidates, including potential
delays in the commencement, enrollment and completion of clinical trials and
Amerimmune’s ability to further develop emricasan for the treatment of
COVID-19, including the complexity and length of studies required to
commercialize emricasan for COVID-19 and potential delays in the completion of
clinical trials, such as the emricasan Phase 1 study for the treatment of
COVID-19; Histogen’s dependence on its collaboration partner, Amerimmune, to
carry out the development of emricasan and the potential for delays in the
timing of regulatory approval; competition in the COVID-19 market and other
markets in which Histogen and its collaboration partner operate; the potential
that earlier clinical trials and studies of Histogen’s product candidates
may not be predictive of future results; risks related to business
interruptions, including the outbreak of COVID-19 coronavirus, which could
seriously harm Histogen’s financial condition and increase its costs and
expenses; and the requirement for additional capital to continue to advance
these product candidates, which may not be available on favorable terms or at
all. The foregoing review of important factors that could cause actual events
to differ from expectations should not be construed as exhaustive and should
be read in conjunction with statements that are included herein and elsewhere,
including those risks discussed in Histogen’s filings with the Securities
and Exchange Commission. Except as otherwise required by law, Histogen
disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a result of new
information, future events, or circumstances or otherwise.


Susan A. Knudson
Executive Vice President & CFO 
Histogen Inc. 


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.